Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 3
Once sponsors decide to capture/share expanded access-derived data above and beyond that needed, what should IRBs do?
right to try
-
Read more: Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 3 -
Read more: Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 2 Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 2
In some cases there may be value in collecting “real world data” from Expanded Access.
-
Read more: Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 1 Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 1
Expanded access allows patients who lack other treatment options to try unapproved medical products in development.
-
Read more: Expanding The Right to Try Unproven Treatments: A Dangerous, Deregulatory Proposal Expanding The Right to Try Unproven Treatments: A Dangerous, Deregulatory Proposal
As has been proven time and again, “gut feeling” and wishful thinking have never been shown to replace controlled clinical testing.
-
Read more: Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson
In this video explainer, Christopher Robertson discusses the Right to Try Act and off-label use of pharmaceuticals with Alison Bateman-House.
